Abstract:The successful clinical application of immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to immunotherapy, however, their drawbacks such as limited specificity, persistence and toxicity haven't met the high expectations on efficient cancer treatments. Therapeutic cancer vaccines which instruct the immune system to capture tumor specific antigens, generate long-term immune memory and specifically eliminate cancer cells gradually become the most promising strategies to eradicate tumor. However, the disadvantages of some existing vaccines such as weak immunogenicity and in vivo instability have restricted their development. Nanotechnology has been recently incorporated into vaccine fabrication and exhibited promising results for cancer immunotherapy. Nanoparticles promote the stability of vaccines, as well as enhance antigen recognition and presentation owing to their nanometer size which promotes internalization of antigens by phagocytic cells. The surface modification with targeting units further permits the delivery of vaccines to specific cells. Meanwhile, nanocarriers with adjuvant effect can improve the efficacy of vaccines. In addition to classic vaccines composed of antigens and adjuvants, the nanoparticle-mediated chemotherapy, radiotherapy and certain other therapeutics could induce the release of tumor antigens in situ, which therefore effectively simulate antitumor immune responses. Such vaccine-like nanomedicine not only kills primary tumors, but also prevents tumor recurrence and helps eliminate metastatic tumors. Herein, we introduce recent developments in nanoparticle-based delivery systems for antigen delivery and in situ antitumor vaccination. We will also discuss the remaining opportunities and challenges of nanovaccine in clinical translation towards cancer treatment.

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy

Biomaterials-assisted Construction of Neoantigen Vaccines for Personalized Cancer Immunotherapy

Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review

Nanoparticle-mediated Tumor Vaccines for Personalized Therapy: Preparing Tumor Antigensin Vivoorex Vivo?

Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective

Personalized Neoantigen Vaccination with Synthetic Long Peptides: Recent Advances and Future Perspectives

Personalized nanovaccines for treating solid cancer metastases

Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies

Nanoparticle Cancer Vaccines: Design Considerations and Recent Advances

Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Vaccine-like Nanomedicine for Cancer Immunotherapy.

Advancing nanotechnology for neoantigen-based cancer theranostics

Neoantigen Vaccine: an Emerging Tumor Immunotherapy

Research progress of nanovaccine in anti-tumor immunotherapy

Nanomaterial-based cancer immunotherapy: enhancing treatment strategies

Nanovaccines for Cancer Immunotherapy: Current Knowledge and Future Perspectives

Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions

Neoantigens: promising targets for cancer therapy